-
Franks Bryan posted an update 5 months, 4 weeks ago
PRACTICAL APPLICATIONS Previous studies showed that Zanthoxylum alkylamides (ZA) could promote the amino acid metabolism in the jejunum of healthy SD rats, improve protein metabolism disorder of type 1 diabetic rats, and also reduce the risk of metabolic syndrome in fat rats model. Herein, we investigated the effect of ZA on amino acid metabolism in type 2 diabetes mellitus (T2DM) rats. The results indicated that ZA could remarkably improve the abnormal expression of amino acid carriers in the jejunum, liver, and skeletal muscle, thereby ameliorating the disorder of amino acid metabolism in the plasma, jejunum, liver, and skeletal muscle of T2DM rats. selleck kinase inhibitor Therefore, ZA are potential antidiabetic food/medicine product for the T2DM treatment.
Pharmacologic effects were analysed to determine a dose recommendation for oseltamivir in immunocompromised (IC) adults with influenza.
Quantitative clinical pharmacology methods were applied to data from 160 adult IC patients (aged 18-78 years) from two studies (NV20234, 150 patients; NV25118, 10 patients) who received oseltamivir 75-200 mg twice daily for up to 10 days. An established population-pharmacokinetic (PK) model with additional effects on oseltamivir and oseltamivir carboxylate (OC) clearance described the PK characteristics of oseltamivir in IC patients versus otherwise healthy (OwH) patients from previous clinical trials. Estimated PK parameters were used to evaluate exposure-response relationships for virologic endpoints (time to cessation of viral shedding, viral load measures and treatment-emergent resistance). A drug-disease model characterized the viral kinetics of influenza accounting for the effect of OC on viral production.
Oseltamivir clearance was 32.5% lower (95% confidence interval , 26.1-38.8) and OC clearance was 33.7% lower (95% CI, 23.2-44.1) in IC versus OwH patients. No notable exposure-response relationships were identified for exposures higher than those achieved after conventional dose oseltamivir 75 mg, which appeared to be close to the maximum effect of oseltamivir. Simulations of the drug-disease model predicted that initiating treatment within 48 hours of symptom onset had maximum impact, and a treatment duration of 10 days was favourable over 3-5 days to limit viral rebound.
Our findings support the use of conventional-dose oseltamivir 75 mg twice daily for 10 days in the treatment of IC adult patients with influenza.
Our findings support the use of conventional-dose oseltamivir 75 mg twice daily for 10 days in the treatment of IC adult patients with influenza.
Hidradenitis suppurativa (HS) is a chronic inflammatory disorder of hair follicles characterized by recurrent, painful nodules, abscesses, and sinus tracts (“tunnels”) typically refractory to treatment. This debilitating condition results in poor quality of life due to high disease burden. Intralesional triamcinolone (ILTAC) is a standard of care for acute inflammation and drainage associated with HS; however, the optimal therapeutic dose has not been determined. We investigated the utility of high-dose ILTAC 20mg/ml (ILTAC-20) or 40mg/ml (ILTAC-40), for inflammatory lesions of HS.
A retrospective chart review and telephone questionnaire included HS patients treated with high-dose ILTAC-20 or ILTAC-40 between April and December 2018. Patients with Hurley stages I-III were included. Data were obtained from electronic medical records and telephone interviews. A short questionnaire pertained to satisfaction with therapy, changes of disease state, and modifications in quality of life.
Of 54 patients interviewed, the average age was 36.9±11.6years; 36 (66.7%) were female. Forty patients (76.9%) were very satisfied (n=19) or satisfied (n=21) with high-dose ILTAC therapy. Fifty patients (92.6%) demonstrated improvements in disease state, and 41 patients (75.9%) experienced enhanced quality of life. Forty-four patients (86.3%) were amenable to additional injections of high-dose ILTAC, if clinically indicated. No adverse effects of therapy were reported.
The majority of patients reported improvements in disease state, quality of life, and overall satisfaction after administration of high-dose ILTAC (20-40mg/ml). These findings support the use of high-dose ILTAC for acute lesions of HS.
The majority of patients reported improvements in disease state, quality of life, and overall satisfaction after administration of high-dose ILTAC (20-40 mg/ml). These findings support the use of high-dose ILTAC for acute lesions of HS.The hydraulic profiling tool (HPT) is widely used to generate profiles of relative permeability vs. depth. In this work, prior numerical modeling results are used to develop a relationship between probe advance rate V (cm/s), probe diameter D (cm), water injection rate Q (mL/min), corrected pressure Pc (psi), and hydraulic conductivity K (feet/d) where E is an empirically derived hydraulic efficiency factor. The relationship is validated by 23 HPT profiles that, after averaging K vertically, were similar to slug test results in adjoining monitoring wells. The best fit value of E for these profiles was 2.02. This equation provides a physically based approach for generating hydraulic conductivity profiles with HPT tooling.
Minimizing endoscopist exposure to bodily fluids is important for reducing the risk of infection transmission. This study investigated the patient-endoscopist vertical distance necessary to minimize an endoscopist’s facial exposure to a patient’s visible droplets during upper gastrointestinal endoscopy and the ability of a new device to prevent droplets from reaching the endoscopist’s face.
A model was developed to simulate a patient experiencing a forceful cough during an upper gastrointestinal endoscopy with a model endoscopist. Fluorescent dye was expelled from the model patient’s mouth towards the model endoscopist during simulated coughs; dye adhesion to the model endoscopist’s face was evaluated using ultraviolet light. The simulation was repeated with the model patient positioned 70-100cm above the floor, with and without a barrier to shield the patient’s face. The accuracy of the cough simulation model and the relationship between patient-endoscopist vertical distance and endoscopist’s facial exposure were evaluated.